

Haematologica
HAEMATOL/2017/182642
Version 3

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351
for medically less fit adults with newly diagnosed acute myeloid
leukemia or other high-grade myeloid neoplasm

Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N.
McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival,
Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C.
Louie, and Elihu H. Estey

Disclosures: M.T.C. and A.C.L. are employees of Celator Pharmaceuticals/Jazz
Pharmaceuticals. The other authors declare no competing financial interests.

Contributions: R.B.W. and E.H.E. designed the study, contributed to patient recruitment,
participated in data analysis and interpretation, and drafted the manuscript. M.O.
performed all statistical analyses and interpreted data. R.B.W., K.F.O. and E.N.M. collected
and assembled clinical data. B.L.S., P.S.B., M.E.M.M., P.C.H., and B.C.M. contributed to
patient recruitment. M.T.C. and A.C.L. contributed to the conception and design of the
study. All authors critically revised the manuscript.